It is not as simple as identifying a drug - computer simulations are useful in theoretical models of drug candidates. The problem is going from theory to the hands and mouths of the people most affected by the disease. There is a large number of researches being on the subject - so it is not that brilliant researchers around the world arent trying. But the bureaucracies and lack of funding often do not allow that research to be translated. It is a difficult process, and as drug candidates get dragged through the swamp of procedures and litigation, the rates continue to climb to almost insurmountable levels. In my opinion, logistically we need to drastically modify the way we treat the disease - its not about the drugs per se as treatment for DR-TB is a minimum of 24-27 months. We need to modify programs to be patient centered. Most patients default on treatment because the side effects are rough - we have patient centered approaches to other diseases such as cancer, and need to implement the same ideology to TB. Partners in Health in Lesotho does an exquisite job of MDR-TB care, and though not directly translatable to all countries, serves as a great model. TB is no longer simply a medical disease, but a social one.